Clinical Trial Update: Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Expanded Activated Lymphocytes as adjuvant therapy to reduce recurrence in hepatocellular carcinoma after surgical resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Expanded Activated Lymphocytes

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: UNKNOWN